Contineum (CTNM) CMO sells 3,611 shares, receives 160,000 stock options

Rhea-AI Filing Summary

Contineum Therapeutics executive Tim Watkins reported option exercises, share sales, and a new option grant. On 01/28/2026 he exercised 3,611 stock options at an exercise price of $4.50 per share, acquiring 3,611 shares of Class A common stock.

That same day, he sold 2,800 shares at a weighted average price of $14.0861 and 811 shares at a weighted average price of $14.4848, leaving no directly held common shares after the transactions. These sales were made under a Rule 10b5-1 trading plan adopted on September 23, 2025.

In a separate transaction on 01/30/2026, Watkins received an award of 160,000 stock options with a $14.26 exercise price, expiring on 01/29/2036. These options vest in equal monthly installments over 48 months, subject to his continuous service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Watkins Tim

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CMO & Head of Development

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/28/2026		M(1)		3,611	A	$4.5	3,611	D
Class A Common Stock	01/28/2026		S(1)		2,800	D	$14.0861(2)	811	D
Class A Common Stock	01/28/2026		S(1)		811	D	$14.4848(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.5	01/28/2026		M(1)			3,611	(4)	04/27/2035	Class A Common Stock	3,611	$0	252,778	D
Stock Option (right to buy)	$14.26	01/30/2026		A		160,000		(5)	01/29/2036	Class A Common Stock	160,000	$0	160,000	D

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $14.39, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $14.53, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

4. One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.

5. Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service.

	/s/ Peter Slover, Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CTNM CMO Tim Watkins report on this Form 4?

Tim Watkins reported exercising 3,611 stock options at a $4.50 exercise price and selling all 3,611 resulting Class A common shares in two trades, plus receiving a new grant of 160,000 stock options with a $14.26 exercise price.

How many Contineum Therapeutics (CTNM) shares did Tim Watkins sell and at what prices?

On January 28, 2026, Tim Watkins sold 2,800 CTNM Class A common shares at a weighted average price of $14.0861 and 811 shares at a weighted average price of $14.4848, disposing of all 3,611 shares acquired from option exercises.

What new stock options did CTNM grant to Tim Watkins in this filing?

Contineum Therapeutics granted Tim Watkins 160,000 stock options with a $14.26 exercise price, expiring January 29, 2036. The options were issued under the 2024 Equity Incentive Plan and vest in equal monthly installments over 48 months, contingent on continuous service.

Were Tim Watkins’ CTNM share sales pre-planned under a 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by Tim Watkins on September 23, 2025. Such plans pre-schedule trades, helping executives sell shares over time under predetermined instructions.

What happens to the exercised CTNM options after Tim Watkins’ transactions?

Watkins exercised 3,611 options at a $4.50 exercise price, converting them into 3,611 Class A common shares, which he then sold. After the exercise, the derivative table shows 252,778 stock options remaining beneficially owned directly, separate from the newly granted 160,000 options.

What is Tim Watkins’ role at Contineum Therapeutics (CTNM) according to this Form 4?

The Form 4 lists Tim Watkins as an officer of Contineum Therapeutics, serving as Chief Medical Officer (CMO) & Head of Development. He is not identified as a director or a 10% owner in the reporting person information.